Obermatt
See Similar Stocks →

GH Research

NMQ:GHRS · IE000GID8VI0
PharmaceuticalsSmall

360° View

57
Price/Sales—
Price/Earnings100
Price/Book16
Dividend Yield1
Revenue Growth—
Profit Growth9
Capital Growth100
TSR 52w91
Leverage97
Liquidity4
Refinancing38
Combined54
Analyst Opinions55
Pro Holdings66
Opinion Changes50
Market Pulse33

Profile

CountryIreland
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2021
Employees70
ISINIE000GID8VI0
Last UpdateApr 2, 2026
Index & Theme
PsychiatryNeurologyPsychedelic-Based TherapyCentral Nervous SystemBiopharmaBiotechnologyPharmaceutical

Description

GH Research PLC operates as a clinical-stage biopharmaceutical company. The company is dedicated to transforming the lives of patients by developing practice-changing treatments for depression. Its initial focus is on developing novel and proprietary…

Analysis

GH Research's 360° View rank of 57 places it above its peer average — better than 57% of its true peers.

It's a growth standout (79) and on the expensive side (42). On safety it is carrying more balance-sheet risk (33), and the market shows favorable sentiment (52). Taken together, its Combined rank of 54 reads as above its peer average.

360° rank · history

1007550250
57
2026

All-time high

57

Jun 2026

All-time low

32

Mar 2026

Average rank

45

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
—
—
—
—
Price/Earnings
100
—
—
—
Price/Book
16
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
42
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare GH Research with its peers
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mediwound
NMQ:MDWD
25
CountryIsrael
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PolyPid
NAQ:PYPD
26
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Sealsq
NSQ:LAES
4
CountrySwitzerland
IndustrySemiconductors & Semiconductor Equipment
SizeSmall
Full Stock Analysis →
Pentixapharm
GER:PTP
22
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →